Administrative Core

Marce联盟促进了有助于保卫美国人口的研究 美利坚合众国反对生物威胁，包括故意释放生物恐怖制剂和自然 传染病的出现或再次出现。作为其正式确定的任务的一部分，Marce还 与大西洋中部地区的公共卫生当局保持互动，以便在需要时， 该财团可以调动其技术资源，帮助该地区的公共卫生当局面对 大规模或不寻常的疾病爆发，推定为生物恐怖事件或其他灾难。《马西》 拟议2009-2014年供资周期的联合体(MARCE-2)包括大约65个 来自27个研究机构的科学家将参与一系列合作研究项目(The 其中绝大多数代表跨越机构边界的合作)。迈伦·M博士。 莱文，医学博士，D.T.P.H.，格罗尔曼杰出教授兼疫苗中心主任 马里兰大学医学院的发展，将继续担任校长 调查员兼Marce局长。艾莉森·奥布莱恩博士，博士，教授兼 健康科学统一服务大学的微生物学将继续担任联合 首席调查员。A4节中的图4-1提供了MARCE-2的组织结构图。

The MARCE consortium fosters research that contributes to the defense of the population of the United States of America against biological threats including the deliberate release of bioterror agents and the natural emergence or re-emergence of infectious diseases. As part of its formally defined mission, the MARCE also maintains interactions with public health authorities within the Middle Atlantic Region so that if the need arises, the consortium can mobilize its technical resources to assist the region's public health authorities in the face of a large or unusual outbreak of disease, presumed bioterror incident or other catastrophe. The MARCE consortium that is proposed for the funding cycle of 2009-2014 (MARCE-2) encompasses approximately 65 scientists from 27 research institutions who will engage in a series of collaborative research projects (the vast majority of which represent collaborations that extend across institutional boundaries). Dr. Myron M. Levine, M.D., D.T.P.H., the Grollman Distinguished Professor and Director of the Center for Vaccine Development of the University of Maryland School of Medicine, will continue to serve as the Principal Investigator and Director of the MARCE. Dr. Alison O'Brien, Ph.D., Professor and Chair of the Department of Microbiology of the Uniformed Services University of the Health Sciences, will continue to serve as Co- Principal Investigator. Figure 4-1 in Section A4 provides an overview organizational chart of MARCE-2.